Publicaciones en las que colabora con CARLOS CAMPS HERRERO (22)

2024

  1. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 1, pp. 190-215

2023

  1. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

    Annals of Surgical Oncology, Vol. 30, Núm. 2, pp. 1225-1235

  2. ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

    Annals of surgical oncology, Vol. 30, Núm. 2, pp. 1238-1239

2022

  1. Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 13

2021

  1. Characterization of circulating t cell receptor repertoire provides information about clinical outcome after pd-1 blockade in advanced non-small cell lung cancer patients

    Cancers, Vol. 13, Núm. 12

2019

  1. Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer

    Cell Death and Disease, Vol. 10, Núm. 9

2018

  1. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

    Journal of Thoracic Oncology, Vol. 13, Núm. 3, pp. 413-425

  2. High-throughput screening of new drugs targeting lung CSCs

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii668

2017

  1. Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients

    OncoImmunology, Vol. 6, Núm. 1

  2. MicroRNA profiling associated with non-small cell lung cancer: Next generation sequencing detection, experimental validation, and prognostic value

    Oncotarget, Vol. 8, Núm. 34, pp. 56143-56157

2016

  1. 114P: Expression analysis of tumorspheres from non-small cell lung cancer show significant differences in CSC-markers and signaling pathways

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S105

  2. 62P Novel therapeutic strategies in NSCLC: Lung-tumorspheres as an effective in vitro screening platform

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S81

  3. Analysis of the immune microenvironment in resected non-small cell lung cancer: The prognostic value of different T lymphocyte markers

    Oncotarget, Vol. 7, Núm. 33, pp. 52849-52861

2014

  1. A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer

    Annals of Surgical Oncology, Vol. 21, Núm. 2, pp. 612-620

2011

  1. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer

    Journal of Thoracic Oncology, Vol. 6, Núm. 2, pp. 286-290

  2. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

    Clinical and Translational Oncology, Vol. 13, Núm. 6, pp. 411-418

  3. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

    Lung Cancer, Vol. 72, Núm. 3, pp. 365-369

2010

  1. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non - small-cell lung cancer

    Journal of Clinical Oncology, Vol. 28, Núm. 19, pp. 3138-3145

1998

  1. Cisplatino e ifosfamida en el carcinoma epidermoide de cabeza y cuello recurrente o metastatico

    Oncologia, Vol. 21, Núm. 5, pp. 57-62

  2. Estudio fase II de combinacion de cisplatino e ifosfamida como tratamiento neoadyuvante en carcinomas epidermoides avanzados de cabeza y cuello

    Oncologia, Vol. 21, Núm. 5, pp. 50-56